Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.56 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 2/20 | 0.41 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MLNR | O43193 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16258028 | 1.00 | CYP17A1 (0.56) | CYP17A1CYP11B1CYP11B2KIF11RARB | |
| SCHEMBL16258055 | 1.00 | CYP17A1 (0.56) | CYP17A1CYP11B1CYP11B2KIF11RARB | |
| SCHEMBL8990898 | 0.94 | CYP17A1 (0.51) | CYP17A1CYP11B1CYP11B2KIF11RARB | |
| SCHEMBL16257976 | 0.91 | CYP17A1 (0.49) | CYP17A1CYP11B1CYP11B2KIF11RARB | |
| SCHEMBL16258016 | 0.91 | CYP17A1 (0.49) | CYP17A1CYP11B1CYP11B2KIF11RARB | |
| SCHEMBL16258035 | 0.91 | CYP17A1 (0.49) | CYP17A1CYP11B1CYP11B2KIF11RARB | |
| SCHEMBL16258045 | 0.88 | CYP17A1 (0.46) | CYP17A1CYP11B1CYP11B2RARBRARA | |
| SCHEMBL18416776 | 0.88 | CYP17A1 (0.46) | CYP17A1CYP11B1CYP11B2RARBRARA | |
| SCHEMBL3153827 | 0.87 | CYP1A2 (0.50) | CYP17A1CYP11B1CYP11B2KIF11RARB | |
| SCHEMBL19301066 | 0.85 | CYP17A1 (0.46) | CYP17A1CYP11B1CYP11B2KIF11RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9752075-B2 | Mesogenic media and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-20170210990-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20160298031-A1 | MESOGENIC MEDIA AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160289561-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160024383-A1 | LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT USING THE SAME | DIC CORPORATION (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024383-A1 | LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT USING THE SAME | DIC CORPORATION (JP) | 2016-01-28 | — | — | US | disclosed |
| EP-2806011-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | DIC Corporation (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455061-B2 | Optically active compound having polymerizable group and its polymer | JNC CORPORATION (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110086185-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND AND ITS POLYMER | CHISSO CORPORATION (JP) | 2011-04-14 | — | — | US | disclosed |
| US-20100297367-A1 | OPTICALLY ANISOTROPIC SUBSTANCE | CHISSO CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100096591-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND POLYMER | CHISSO CORPORATION | 2010-04-22 | — | — | US | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| EP-1218361-B1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100096591-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND POLYMER | PKN1, ZYX, OXER1 | CYP17A1 191/4885CYP11B1 52/4885CYP11B2 193/4885 |
| US-20110086185-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND AND ITS POLYMER | CCNT1, POF1B, CCND3 | CYP17A1 1784/4885CYP11B1 2947/4885CYP11B2 3238/4885 |
| US-20160289561-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | CYP17A1 2476/4885CYP11B1 1613/4885CYP11B2 1457/4885 |
| US-20170210990-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | CYP17A1 2299/4885CYP11B1 1497/4885CYP11B2 1424/4885 |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A2, GUCY1A1 | CYP17A1 605/4885CYP11B1 215/4885CYP11B2 231/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | CYP17A1 605/4885CYP11B1 215/4885CYP11B2 231/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | CYP17A1 1178/4885CYP11B1 522/4885CYP11B2 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.